PND66 Treatment Patterns for Parkinson’s Disease: Real-World Evidence from the EU5 (France, Germany, Italy, Spain, and the United Kingdom)  by Sung, A.H. et al.
A630  VA L U E  I N  H E A LT H  1 6  ( 2 0 1 3 )  A 3 2 3 – A 6 3 6  
Objectives: Diagnosis of urinary tract infection (UTI) in young children is difficult. 
Prompt treatment could alleviate short-term symptoms and prevent serious long-
term sequelae, but over-treatment will increase antibiotic resistance. We evaluated 
the cost-effectiveness of a UTI risk score based on signs, symptoms and dipstick test 
findings compared to clinical judgement in guiding urine sampling and antibiotic 
treatment. MethOds: We developed a risk score based on urine samples collected 
(by clean catch or nappy pad) in a multicentre diagnostic cohort study (DUTY) of 
7,163 children < 5 years presenting to primary care. The diagnostic value of symp-
toms, signs and dipstick test results were evaluated against a reference standard of 
urine culture results from a research laboratory. We constructed decision-analytical 
models comparing the cost-effectiveness of 3 DUTY risk score thresholds (high 
sensitivity, high specificity or intermediate) versus clinical judgement in younger 
(nappy pad) and older (clean catch) children. We explored the role of the dipstick 
in guiding diagnosis. We considered health service costs and patient utilities dur-
ing the initial diagnosis, acute illness and long-term sequelae. Results: The ‘high 
specificity’ DUTY threshold resulted in fewer urine samples than clinical judgement 
(4.8% vs. 9.2%) with similar sensitivity (58.6% vs. 57.1%) and higher specificity (96.1% 
vs. 91.4%). The difference in short-term net benefits between DUTY thresholds was 
small (range £1088 ‘high sensitivity’ to £1091 ‘high specificity’). In younger children 
(nappy pads) the distinction in cost-effectiveness between the DUTY risk score 
and clinical judgement was not clear-cut. Dipstick tests could potentially expedite 
therapy in higher risk children. cOnclusiOns: Clinicians can reduce prescriptions 
and provide more cost effective care by using the DUTY risk score. Clean catch 
samples should be obtained whenever practical. Low UTI prevalence, imperfect NHS 
laboratory tests and an uncertain link between UTI and long-term sequelae mean 
that conservative sampling strategies may be most appropriate.
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Objectives: This research was carried out during a review of the manufacturer’s 
submission (MS) to the NICE Single Technology Appraisal programme for the 
selective beta3-adrenoceptor agonist, mirabegron. Antimuscarinics are the main-
stay of treatment for the symptoms of OAB. They may be used at different doses 
and in different formulations (immediate release [IR] or extended release [ER]). 
However, there is limited evidence on their comparative clinical effectiveness 
with each other. This research evaluated the available evidence for mirabegron, 
antimuscarinics, and placebo. MethOds: Randomised controlled trials (RCTs) 
for inclusion were identified using the MS for mirabegron. RCTs were assessed 
for comparability based on diagnosis, patient population, treatment regimen, and 
with outcomes reported at 12 weeks. Mixed treatment comparison (MTC) using 
Bayesian Markov Chain Monte Carlo simulation was used to perform a meta-anal-
ysis of a network of RCTs. Summary statistics used were mean difference (MD) for 
continuous outcomes and odds ratio (OR) for dichotomous outcomes. Results: Of 
the 40 RCTs identified in the MS, 22 met the criteria for inclusion in the analysis. 
No statistically significant differences in frequency of micturition were identi-
fied between any of the active treatments. Compared with mirabegron 50mg, 
statistically significant differences in the remaining outcomes assessed, were: 
fewer incontinence episodes, MD (solifenacin 5mg -0.39, 95%CI: -0.72 to -0.06; 
solifenacin 10mg -0.38, 95%CI: -0.69 to -0.07); increased risk of constipation , OR 
(fesoterodine 8mg 2.12, 95%CI: 1.13 to 3.64; solifenacin 5mg 2.11, 95%CI: 1.16 to 
3.59; solifenacin 10mg 4.52, 95%CI: 2.60 to 7.47; trospium 60mg 7.63, 95%CI: 2.12 to 
22.95); increased risk of discontinuation, OR (oxybutynin 15mg IR 2.67, 95%CI: 1.60 
to 4.22). Mirabegron was associated with significantly lower risk of dry mouth than 
all other active treatments. cOnclusiOns: None of the treatments assessed for 
OAB have a consistently superior efficacy with a reduced risk of adverse events.
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Objectives: Acute renal failure is responsible for about 1% of hospital admissions, 
and occurs in up to 7% of hospitalized patients and up to 20% of patients admitted to 
intensive care units (ICU’s). When it is severe enough to require dialysis, in-hospital 
mortality rate ranges from 50% to 75% and is also increases risk for chronic and 
terminal kidney diseases. Continuous Renal Replacement Therapy (CRRT) in its 
various forms has theoretical advantages over conventionally done Intermittent 
Hemodialysis (IHD) at significantly higher costs, but these advantages attributed to 
CRRT have not yet been consistently proven in terms of clinical outcomes in con-
trolled trials. MethOds: We have made a literature search in PubMed to identify 
systematic reviews and randomized controlled trials that studied patient-oriented 
outcomes (mortality and renal recovery). Results: We have found five systematic 
reviews published in 2007 and 2008 and conducted our own metanalysis on six trials 
published from 2001 to 2009 (no clinical outcomes oriented trial has been published 
since them). None of the reviews that directly compared CRRT to IHD have shown 
statistically significant advantages of any of them regarding in-hospital or ICU 
mortality or renal function recovery We have analyzed six randomized no-blinded 
clinical trials that met eligibility criteria of evaluating patient-oriented outcomes 
including 1151 patients. Five of them had high to moderate GRADE scores. None 
have shown absolute risk reduction of in hospital, ICU or at 60 days mortality or 
statistically significant renal recovery rates. Overall mortality relative risk of CRRT 
over IHD was 1,01 (95%CI: 0,92 – 1,11). We found moderate heterogeneity and no 
publication bias. cOnclusiOns: Clinical trials published until October 2012 have 
shown no difference in patient-oriented outcomes between the uses of CRRT and 
IHD techniques in adult patients admitted to intensive care units with acute renal 
failure and requiring renal replacement therapy.
and more likely to be Caucasian (64.61% vs. 41.53%, p< 0.001) than national cohort 
patients. DS patients in Utah suffered significantly more comorbidities: autism 
(6.43% vs. 1.12%, p< 0.001), heart problems (2.53% vs. 0.57%, p< 0.001), blood and 
blood-forming problems (14.81% vs. 10.05%, p< 0.001), epilepsy (7.02% vs. 2.23%, 
p< 0.001) and arthritis (28.46% vs. 10.68%, p< 0.001). Higher proportions of Utah 
patients used ulcer drugs (21.64% vs. 16.83%, p< 0.005), majority PPIs (85.6%); 
antidepressants, (17.93% vs. 11.55%, p< 0.001), majority SSRIs (79.3%); analgesics-
NSAIDs (15.59 % vs. 11.13%, p< 0.005), majority NSAIDs (98.8%); multivitamins 
(16.18% vs. 9.02%, p< 0.001), and fluoroquinolones (10.53% vs. 7.45%, p< 0.01) than 
the national cohort. cOnclusiOns: The Utah DS population differs from the 
comparative U.S. Cohort in demographics, comorbidities and medications. These 
results will be incorporated into the development of a Quality of Life scale to value 
new treatments in Down Syndrome.
Pnd66
treatment Patterns for ParKinson’s disease: real-world evidenCe 
from the eU5 (franCe, Germany, italy, sPain, and the United KinGdom)
Sung A.H.1, Kulkarni A.2, Svarvar P.2
1St. John’s University, Queens, NY, USA, 2Merck & Co., Inc., Whitehouse Station, NJ, USA
Objectives: To assess the distribution of initial Parkinson’s Disease (PD) treat-
ment, along with time to and reasons for changes in therapy. MethOds: Adelphi 
Real-World Disease-Specific-Programme (DSP) cross-sectional PD data from 
January 2011 to February 2012 were analyzed. The DSP surveyed 299 physicians 
in the EU5 who completed PD patient reviews (≥ 10 each). Kaplan-Meier estima-
tion was used to evaluate times from initial monotherapy to follow-up therapy 
by treatment. Reasons for adding or switching drug classes were documented 
as efficacy-related, levodopa-related (dyskinesia or on-off fluctuations), due to 
side-effects, and/or other reasons. Results: Of the 3,351 patients included, 60% 
were male; mean age at treatment initiation was 65 years; 55% had mild Hoehn & 
Yahr severity scores (≤ 2.5); and 59% initiated treatment on monotherapy. Overall, 
Dopamine Agonists (DA) were the most common first-line monotherapy (45%; 
mean age 62 years), followed by Levodopa (39%; 71 years), Monoamine-oxidase-B 
Inhibitors (MAOB) (14%; 62 years), and Other (2%; 64 years). The median time 
to change from DA monotherapy was 36 months. Levodopa was the first choice 
add-on (16%) and switch from (5%) DA monotherapy. Reasons for change to 
Levodopa were efficacy-related (92% add-on; 70% switch patients). The median 
time to change from Levodopa monotherapy was 54 months. DA was the first 
choice add-on (13%) and switch from (1.4%) Levodopa monotherapy. Reasons for 
change to DA were efficacy-related (86% add-on; 82% switch patients). The median 
time to change from MAOB monotherapy was 12 months. DA was the first choice 
add-on (32%) and switch from (6%) MAOB monotherapy. Reasons for change to 
DA were efficacy-related (95% add-on; 94% switch patients). cOnclusiOns: This 
EU5 sample represents a levodopa-sparing treatment strategy, favoring initiation 
with DA for younger patients. Initial treatment with Levodopa monotherapy was 
of longer duration than that with DA or MAOB. Physicians predominantly reported 
efficacy-related reasons for treatment changes.
Urinary/Kidney disorders – Clinical outcomes studies
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Objectives: Analyze the cost-effectiveness of the prophylaxis (n-acetylcysteine 
1200mg 4 oral-doses+1/6M bicarbonate 500ml IV) of the contrast-induced 
nephropathy (CIN) at risk patients. The CIN is usually reversible, but may affect 
50% of patients with some risk factors (diabetes, age...) and may favor the 
progressive renal damage. MethOds: Retrospective observational study. The 
population were patients candidates at prophylaxis protocol CIN in a university 
hospital during 2012 (5142 patients). We calculated a sample size of 115 patients 
for a confidence level of 90%, an error of 7.5% and a frequency of CIN equal 40% 
. CIN was considered as the relative elevation of serum creatinine greater than 
or equal to 25% during the 48 hours after the test. For the economic analysis 
were used acquisition-costs of drugs, and the hemodialysis costs described by 
Lorenzo et al (Nephrology2010,30(4):404-412). We consider, according to litera-
ture that at least 35% of risk patients affected by NIC would require a hemodi-
alysis session. Results: Of the patients who received prophylaxis, 3 had CIN 
and 93 no. Of those who received no prophylaxis 5 had CIN, and 14 no. We did a 
Fisher Test being the difference in favor of the protective effect of the protocol 
statistically significant (p < 0.01). The prophylaxis would have prevented 25.26 
CIN. The prophylaxis costs per patient were € 2.29 . The cost of a hemodialysis 
sessions was € 423. Then € 220.42 has been invested to avoid a minimum of € 
3739.74 on hemodialysis. (16.9 € savings per euro spent on prophylaxis. Each 
avoided NIC had cost € 8.73.) cOnclusiOns: The economic analysis is difficult 
because of the diversity of data about CIN. We chose a cost-minimization model, 
considering minor treatment needs found in the literature. In any case this 
prophylaxis is highly cost-effective and should be considered before introduc-
ing other methods.
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